drugset / Trial / NCT03739840

A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

NCT03739840

Phase 3 Terminated 232 enrolled UCB Biopharma SRL
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the efficacy, safety and tolerability of the 3 selected dose regimens of padsevonil (PSL) administered concomitantly with up to 3 anti-epileptic drugs (AEDs) compared with placebo for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy.

Timeline

Start
2019-03-06
Primary completion
2020-09-28
Completion
2020-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Padsevonil Small molecule 100 mg
Subject Padsevonil Small molecule 200 mg
Subject Padsevonil Small molecule 400 mg

Indications